A Medical Device Daily
Bio-Matrix Scientific Group (San Diego) reported that its majority owned subsidiary, Entest BioMedical unit, has filed a patent application for the use of adipose derived stem cells in the treatment of chronic obstructive pulmonary disease (COPD).
Bio-Matrix sid that progress has been achieved by Entest in identifying diseases it believes will be treatable through stem cell therapy.
COPD is a major health disorder that appears to be treatable through adipose derived stem cell therapy. Currently, this disease is treated in similar fashion to asthma, with inhalers and/or oxygen therapy. These methods are not solutions to the disease but merely provide the patient with greater level of comfort.
The goal of Entest BioMedical is to develop a stem cell therapy that reverses the effects of COPD on the respiratory system.